J&J’s US OTC Sales Hold Firm As COVID Impact Begins To Bite

 
• By Tom Gallen

Johnson & Johnson US OTC sales a bright spot in a Q2 performance hampered by the COVID-19 pandemic.

Closeup on businessman holding a card with DEMAND rising arrow and chart, business concept image with soft focus background
• Source: Shutterstock

More from Earnings

More from Business